



**FOR IMMEDIATE RELEASE**

16 January 2007

**OXFORD GENE TECHNOLOGY AND AGILENT TECHNOLOGIES ENTER  
INTO A COLLABORATIVE AGREEMENT**

**Oxford and Santa Clara, January 16, 2007** - Oxford Gene Technology (OGT) and Agilent Technologies are pleased to announce the completion of a collaborative agreement giving OGT access to Agilent's microarray platform, confirming OGT as an Agilent Certified Service Provider, and appointing Agilent as an OEM supplier for OGT designed microarrays.

OGT and Agilent, joint pioneers of the development of the Ink Jet *in-situ* synthesis (IJSS) and SurePrint™ platforms, will combine the experience and expertise of OGT in microarray services with Agilent's microarray platform to provide an end-to-end solution, giving the customer a flexible platform using high density, high sensitivity microarrays, tailored to application services.

Combining OGT's experience in custom microarray design and data analysis with Agilent's microarray tools including the Agilent 2100 Bioanalyser™ and GeneSpring™ software suite will enable OGT and Agilent to jointly develop a Centre of (Microarray) Excellence targeting new emerging applications including aCGH, ChIP, methylation and microRNA.

The OEM supply of OGT designed microarrays (by Agilent) will assist OGT in the development of their products, in particular, the recently launched Chip<sup>2</sup>™ prokaryotic ChIP on chip range and products in the development pipeline such as aCGH.

Dr Mike Evans, Chief Executive at OGT said: "OGT and Agilent have always had a close collaborative relationship. This agreement is very exciting for OGT and Agilent as it gives our companies the opportunity to excel as a global Centre of Excellence."

Dr Yvonne Linney, General Manager for Genomics at Agilent, said: "Agilent and OGT share a vision of energizing the discovery process through freedom of experiment design, highly sensitive tools and reproducible results. This close collaboration is the logical extension of this vision to a wider segment of the research community."

- ENDS -

**For further information, please contact:**

**At Oxford Gene Technology:**

Nicola Booton-Mander, Marketing Manager

Oxford Gene Technology  
Begbroke Science Park,  
Sandy Lane, Yarnton  
Oxford OX5 1PF  
T: +44 1865 856352  
F: +44 1865 842116  
E: [services@ogt.co.uk](mailto:services@ogt.co.uk)  
W: [www.ogt.co.uk](http://www.ogt.co.uk)

**Media Inquiries:**

OGT:

Annabel Entress, 0207 886 8150 / [a.entress@northbankcommunications.com](mailto:a.entress@northbankcommunications.com)

Sarah Jeffery, 0207 886 8150 / [s.jeffery@northbankcommunications.com](mailto:s.jeffery@northbankcommunications.com)

Agilent Technologies:

Stuart Matlow, +1 408 553 7191 / [stuart\\_matlow@agilent.com](mailto:stuart_matlow@agilent.com)

**Notes to editors**

**About Oxford Gene Technology**

- Founded in 1995 by the pioneer of Southern Blotting, Professor Sir Edwin Southern, OGT operates out of Begbroke Business Park near Oxford, with excellent access to a growing network of life science companies
- OGT offers a comprehensive custom microarray consultancy service, from experimental design through all stages to data analysis and interpretation. It has a strong proven track record in providing custom microarray service in a range of applications, and recently announced the launch of its first microarray product, an *Escherichia coli* K12 ChIP on chip, the first ChIP microarray product to be launched as part of OGT's Prokaryotic Chip<sup>2</sup> family

**The key focus areas of OGT include:**

1. **Array-based application products and services** for life science research and molecular diagnostics. OGT's flexible and cost-effective, customised DNA microarray service covers a range of applications, offering specialist support and assisting customers with every aspect of their research, from initial consultation and experimental design to probe selection, array design and fabrication through to data analysis and interpretation
2. **Development of innovative platform products** for clinical research and diagnostics

3. **Licensing.** OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays
  
4. **Scientific collaborations** to generate diagnostic biomarker intellectual property

For further information on OGT visit <http://www.oqt.co.uk/>.

**About Agilent Technologies**

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 19,000 employees serve customers in more than 110 countries. Agilent is headquartered in Santa Clara, Calif., and had net revenue of \$5.0 billion in fiscal year 2006. Information about Agilent is available on the Web at [www.agilent.com](http://www.agilent.com).